Lupin Recalls Morphine Sulfate Extended-Release Tablets Due to Impurity
Lupin Pharmaceuticals is recalling specific lots of Morphine Sulfate Extended-Release Tablets because testing found an impurity exceeding safety limits.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which indicates the product is unlikely to cause adverse health consequences. The issue is a failed impurity specification without reported injuries or illnesses.
Plain-English summary
Lupin Pharmaceuticals, Inc. is recalling Morphine Sulfate Extended-Release Tablets, 30 mg, 100-count bottles. The affected product is manufactured by Novel Laboratories, Inc. in Somerset, NJ, and distributed nationwide in the U.S. The specific lot number is S800232, with an expiration date of 2/20.
The recall was initiated because the product failed impurity and degradation specifications. Specifically, testing during 3-month stability analysis and retain testing revealed an out-of-specification result for the Morphinone Sulfate impurity.
Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If the product matches the description, it should be returned to the pharmacy or supplier for replacement or refund. Patients should consult their healthcare provider for alternative pain management options if they are currently using this medication.
The recalled product
- Product
- MORPHINE SULFATE (MORPHINE SULFATE)
- Brand
- MORPHINE SULFATE
- Manufacturer
- LUPIN SOMERSET
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 4,716
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# S800232
- Exp 2/20
UPCs (4)
- 0343386542017
- 0343386543014
- 0343386540013
- 0343386541010
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MORPHINE SULFATE
- CriticalFresenius Kabi Recalls Morphine Syringes Due to Labeling Error
FDA (Drugs) · 2026-08-26
- ModerateMorphine sulfate oral solution recalled over a carton size mismatch
FDA (Drugs) · 2025-12-17
- HighMorphine Sulfate Tablets Recalled Over Failed Dissolution Specifications
FDA (Drugs) · 2025-03-12
- SevereMorphine Sulfate Injection Recalled Due to Defective Vials
FDA (Drugs) · 2021-10-06
- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets for Impurity Failures
FDA (Drugs) · 2019-05-01
Same manufacturer · LUPIN SOMERSET
See all →- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets Due to Impurity Failures
FDA (Drugs) · 2019-05-01
- LowLupin Recalls Morphine Sulfate Extended-Release Tablets Due to Impurity Failures
FDA (Drugs) · 2019-05-01
- ModerateLupin Recalls Morphine Sulfate Tablets for Impurity Specification Failures
FDA (Drugs) · 2019-05-01
- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets for Impurity Failures
FDA (Drugs) · 2019-05-01
- ModerateGavilyte-N Recalled for Incorrect Flavor Labeling on Orange and Cherry Packets
FDA (Drugs) · 2019-04-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17